Concomitant Transverse Myelitis and Guillain-Barré Syndrome Following Varicella-Zoster Virus Infection
Daoliang Lan,Lingyu Liu
DOI: https://doi.org/10.1097/cm9.0000000000002662
2023-01-01
Abstract:To the Editor: Currently known syndromes of acute post-infectious or inflammatory demyelination include acute disseminated encephalomyelitis, encephalitis, transverse myelitis (TM), and Guillain–Barré syndrome (GBS). Demyelination is frequently limited to the central or peripheral nervous systems. The coexistence of myelitis and demyelinating peripheral neuropathy has only been reported in a few children[1,2] and young adults.[3] Also, concomitant TM and GBS in elderly immunocompetent patients has been rarely described. Varicella-zoster virus (VZV) is a well-known pathogenic human herpes virus that causes chickenpox or herpes zoster. It can also cause diverse neurological dysfunction, including encephalitis, myelopathy, peripheral neuropathy, neuralgia, and stroke.[4] Both GBS and acute TM are unusual complications caused by VZV infection.[5] Most VZV patients with GBS or TM achieve excellent outcomes at 1 year (able to walk) after treatment,[6] while the coexistence of GBS and TM caused by VZV infection is very rare, and its treatment strategy and prognosis are not clear. Herein, we reported a case of an immunocompetent man who developed TM and GBS after a VZV infection, the consent form was obtained from the patient. A 58-year-old man presented with neck pain, progressive numbness, and weakness in all limbs, which lasted for 4 weeks. The symptoms progressed rapidly; and soon, he could not sit or stand. The strength in the proximal and distal muscles of the limbs was Medical Research Council (MRC) grade 3/5 and 0/5, respectively. Tendon reflexes were absent in all limbs. Bilateral Babinski's signs were positive. Bilateral pinprick sensation below the C4 level was impaired. The muscles of the limbs were atrophied. He also had defecation dysfunction and urine retention. One month before onset, he developed herpes zoster on the right upper limb and was not treated with acyclovir. Serum and cerebrospinal fluid (CSF) tests for anti-ganglioside, aquaporin 4 (AQP4), myelin oligodendrocyte glycoprotein (MOG), and myelin basic protein (MBP) antibodies were negative. CSF analysis showed a normal white blood cell (WBC) count (4 cells/μL), high protein (92.6 mg/dL), normal glucose, normal immunoglobulin G (IgG) index, and negative CSF oligoclonal bands. VZV antibodies (IgG) were positive in serum and CSF. Polymerase chain reaction (PCR) tests of the CSF for VZV DNA were positive. The MRI of his spine revealed extensive patchy and linear intramedullary lesions with high signal change on T2-weighted MRI from C3 to T2 [Figure 1]. Enhanced cervical MRI showed no significant enhancement of the cervical spinal cord and nerve roots. Nerve conduction studies revealed significantly decreased nerve conduction velocity and reduced compound muscle action potential amplitudes [Supplementary Table 1, https://links.lww.com/CM9/B511]. Bilateral sural sensory, median, and ulnar motor responses were absent. In addition, there was no F response in the bilateral common peroneal nerves and tibial nerves.Figure 1: Cervical spinal magnetic resonance imaging (24 days after onset). (A) High signal intensity on sagittal T2-weighted images within the spinal cord from C3 to T2. (B) An axial T2-weighted image.On the second day in the hospital, he was treated with intravenous acyclovir 500 mg every 8 h for 7 days, immunoglobulin at 0.4 g∙kg-1∙day-1 for 5 days, and intravenous administration of methylprednisolone at 500 mg/day for 6 days. One month later, the strength in his proximal and distal muscles of the extremities was MRC grade 4/5 and 2/5, respectively. The pinprick sensory level decreased to the T4 level. After 6 months, there was very little improvement in his limb power and sensory abnormalities. At 1 year, this patient was still not able to walk independently. Based on the clinical performance, MRI evidence, neuroelectrophysiological findings, and pathogen data, the final diagnosis was VZV-induced TM and acute motor and sensory axonal neuropathy (AMSAN). The pathogenesis of neurological complications related to VZV infection is unclear. Pathologic and virologic analyses of the spinal cord from fatal cases have shown invasion of VZV in the parenchyma; in some cases, invasion of the adjacent nerve roots was also involved.[7] Therefore, the direct invasion of VZV may be one of the reasons for neuropathy caused by VZV. Until now, the pathophysiology of VZV GBS was usually considered to be an immune-mediated post-infectious mechanism. In this patient, we detected positive VZV antibodies and VZV DNA in the CSF. Although anti-ganglioside antibodies were negative, we suggest that the pathogenesis of TM and GBS is related to the direct invasion of the virus and the autoimmune mechanism secondary to infection. Although a standard treatment policy for VZV-induced neurological dysfunction has not yet been established, early diagnosis and aggressive treatment with sufficient acyclovir have been considered helpful in some cases.[8] We also believe that early antiviral therapy is not enough to avoid or mitigate the post-infective autoimmune response. It is well established that TM responds to steroids or immunoglobulin, and GBS responds to immunoglobulin or plasma exchange. Therefore, combined intravenous immunoglobulin and corticosteroid administration is recommended for patients with concomitant TM and GBS.[2,3] Accordingly, this patient was treated with a high dose of intravenous acyclovir, immunoglobulin, and methylprednisolone. Although his muscle strength slightly improved and the level of sensory disturbance significantly decreased, the patient could not walk independently. This patient might have residual or permanent neurological dysfunctions even after the appropriate treatment. There were two possible reasons for this result. First, he began treatment 4 weeks after the onset of the disease; delayed treatment might be the first reason for his poor prognosis. Second, immunoglobulin and steroids might not be effective enough for AMSAN. Therefore, we suggest that early medical intervention may be helpful for better and earlier recovery. Of course, this suggestion has not been supported by strong evidence and still needs more clinical trials to discuss. This report presents a rare microbiologically confirmed case of concurrent TM and AMSAN following VZV infection in an immunocompetent patient. Our data suggest using the VZV antibody and DNA in the CSF to confirm this disease. In addition, we suggest that early diagnosis and early administration of acyclovir, corticosteroids, immunoglobulin, or plasma exchange may be helpful for the rehabilitation of this disease. Funding This study was supported by a grant from the Shanghai Municipal Science and Technology Major Project (No. 2021SHZDZX0100) and the Fundamental Research Funds for the Central Universities. Conflicts of interest None.